Adjunctive Benefits of Systemic Etoricoxib in Non‐Surgical Treatment of Aggressive Periodontitis: Short‐Term Evaluation

Azoubel, Maria Cecília Fonsêca; Sarmento, Viviane Almeida; Cangussú, Virna; Azoubel, Eduardo; Bittencourt, Sandro; Cunha, Fernando; Ribeiro, Ronaldo A.; Brito, Gerly Anne Castro

doi:10.1902/jop.2008.080019

Cited by 21 publications

(36 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Metronidazole affects specifically the anaerobic oral flora, including P. gingivalis, T. forsythia and T. denticola, microorganisms attached to the red Socransky's complex 50 , while A. actinomycetemcomitans, an optional anaerobic bacterium, appears to be widely opposed by the amoxicillin 38-39,41. The anti-inflammatory effect in the AP treatment was not observed. In addition, the studies with these drugs have inconsistent data and, therefore, do not allow any indication [46][47] .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Auxiliary chemical therapies in the treatment of aggressive periodontitis: current aspects

Ayub

Júnior

Grisi

et al. 2015

RGO, Rev. Gaúch. Odontol.

View full text Add to dashboard Cite

Aggressive periodontitis, a distinct clinical entity of periodontal disease, is characterized by a pronounced episodic and rapid destruction of periodontal tissues and may result in rapid and RESUMOA periodontite agressiva, uma entidade clínica distinta da doença periodontal, é caracterizada por uma pronunciada destruição episódica e rápida dos tecidos periodontais e pode resultar em perda rápida e precoce dos dentes. Alguns trabalhos têm mostrado que o debridamento mecânico convencional juntamente com higiene oral muitas vezes não é suficiente para o controle da doença. Apesar de não existir consenso, estudos recentes desta condição mostram efeitos benéficos de terapias auxiliares ou coadjuvantes como a administração de antimicrobianos sistêmicos e locais. Entre os coadjuvantes locais, a literatura apresenta os antissépticos, antibióticos e terapia fotodinâmica. Dentre os sistêmicos são representados os antibióticos e antiinflamatórios. Independentemente dos resultados apresentados por cada um deles, se reconhece a dificuldade em se estabelecer um protocolo único para todos os casos em função da resposta individual apresentada por cada paciente. O objetivo do presente estudo foi revisar os resultados atuais sobre administração de coadjuvantes químicos associados à terapia convencional em casos de periodontite agressiva e sugerir protocolos clínicos.Termos de indexação: Periodontite agressiva. Antibacterianos. Anti-infecciosos locais. Antissépticos bucais. Anti-inflamatórios. Fotoquimioterapia. and alveolar bone destruction and c) family concentration of cases. The diagnosis of AP requires the exclusion of systemic diseases that may harm the host defense and lead to premature teeth loss (periodontal manifestations of systemic diseases). Auxiliary chemical therapies in the treatment of aggressive periodontitis: current aspectsThe existence of particular forms of AP was also recognized based on specific clinical and lab characteristics: localized aggressive periodontitis (LAP) and generalized aggresssive periodontitis (GAP) 2 .A successful treatment of AP is dependent of early diagnosis, directing the therapy to the elimination or deletion of pathogens, providing a favorable

show abstract

Section: Discussionmentioning

confidence: 99%

“…The etoricoxib was unable to promote additional benefits to clinical parameters when compared to conventional treatment 46 .…”

Section: Anti-inflammatorymentioning

confidence: 96%

Auxiliary chemical therapies in the treatment of aggressive periodontitis: current aspects

Ayub

Júnior

Grisi

et al. 2015

RGO, Rev. Gaúch. Odontol.

View full text Add to dashboard Cite

show abstract

“…NSAIDs are considered an important pharmacologic class of agents that act as modulators of the host response, modifying the progression of periodontal disease, as evidenced by animal studies [10,11,15]. Although some evidences are controversial, clinical data have also shown that the systemic administration of these drugs may offer supplementary benefits in periodontal therapy when combined with scaling and root planning [12-14]. However, the systemic use of both non-selective and selective inhibitors of COX-2 are frequently linked to various side effects, including gastroduodenal and renal complications, impairing patient compliance to their use, especially when continued periods of administration are required [16].…”

Section: Discussionmentioning

confidence: 99%

Protective effect of topical Cordia verbenacea in a rat periodontitis model: immune-inflammatory, antibacterial and morphometric assays

Pimentel

Barrella

Casarin

et al. 2012

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundThis study evaluated the effects of C. verbenacea essential oil topically administered in a rat periodontitis model.MethodsPeriodontitis was induced on rats in one of the mandibular first molars assigned to receive a ligature. Animals were randomly divided into two groups: a) non-treatment group (NT) (n = 18): animals received 1mL of vehicle; b) C. verbenacea group (C.v.) (n = 18): animals received 5mg/Kg of essential oils isolated from C. verbenacea. The therapies were administered topically 3 times daily for 11 days. Then, the specimens were processed for morphometric analysis of bone loss. The ligatures were used for microbiological assessment of the presence of Aggregatibacter actinomycetemcomitans, Tannerella forsythia and Porphyromonas gingivalis using PCR. The gingival tissue was collected to Elisa assay of interleukin (IL)-1α and IL-10 levels.ResultsBone loss was inhibited by C. verbenacea when compared to the NT group (p < 0.05). A decrease in the levels of IL-1α and increase in the IL-10 amounts was observed in the C.v. group as compared to NT group (p < 0.05). A lower frequency of P. gingivalis was found in C.v. group (p < 0.05).ConclusionC. verbenacea essential oil topically administered diminished alveolar bone resorption, promoting a positive local imbalance in the pro/anti-inflammatory system and reducing the frequency of detection of P. gingivalis.

show abstract

“…Azoubel et al [16] found no improvement in the clinical parameters regarding the use of Etoricoxib 120 mg/day, but verified the reduction of PGE2 levels in crevicular fluid, which could be related to the slight improvement in bone condition in the non-surgical treatment of aggressive periodontitis. Yen et al [15], in a study with 131 patients for the treatment of chronic periodontitis, found that celecoxib is an effective drug in addition to scaling and root planing, providing better treatment outcomes by reducing the progression of bone loss.…”

Section: Coxibs In Dentistry: An Updatementioning

confidence: 99%

Inibidores seletivos da cox-2 na odontologia: limitações e efeitos adversos

Souza

Caldas

Silva

2016

Rev. Odonto Ciênc. (Online)

View full text Add to dashboard Cite

The coxibs are nonsteroidal anti-inflammatory drugs (NSAIDs) highly selective for COX-2, an enzyme related to inflammatory processes. At first, their use should present advantages over nonselective NSAIDs, since the inflammatory efficacy would be present but with minimal adverse effects. However, its widespread use showed significant cardiovascular risk and, in treatment over 6 months, predisposition to ulceration, bleeding and stomach pain. The coxibs should be used in patients over 60 years, with a history of peptic ulcer or gastrointestinal bleeding, chronic users of corticosteroids and anticoagulants without concomitant cardiovascular risk. Moreover, they are more expensive and have similar analgesic efficacy to non-selective NSAIDs. In dentistry, the main indications are related to the control of pain and inflammation for a maximum of 3 days or preemptively in oral surgery to control pain and swelling. However, there is no major evidence of the benefits of using these drugs compared to traditional NSAIDs in dentistry.Key words: Dentistry; Anti-Inflammatory agents; Cyclooxygenase 2 inhibitors; Adverse effects; Therapeutic use; Contraindications Inibidores seletivos da cox-2 na odontologia: limitações e efeitos adversos ResumoOs coxibes são antiinflamatórios não-esteroidais (AINEs) altamente seletivos para a COX-2, enzima relacionada à processos inflamatórios. A princípio, seu uso deveria apresentar vantagens em relação aos não-seletivos, pois permaneceria a eficácia antiinflamatória com um mínimo de efeitos adversos. Entretanto, sua ampla utilização revelou significativo risco cardiovascular e, em tratamento acima de 6 meses, predisposição à ulcerações, hemorragias e dor gástricas. Sendo recomendado seu uso em pacientes acima de 60 anos, com histórico de úlcera gástrica ou hemorragia digestiva, usuários crônicos de corticosteóides e anticoagulantes. Além disto, são mais caros e possuem eficácia analgésica similar aos AINEs não-seletivos. Em odontologia suas principais indicações estão relacionadas ao controle da dor e da inflamação pelo período máximo de 3 dias ou preemptivamente em cirurgias orais para controle da dor e edema. Entretanto, não há evidências de maiores benefícios da utilização destes fármacos em relação aos AINES tradicionais no manejo odontológico.

show abstract

Adjunctive Benefits of Systemic Etoricoxib in Non‐Surgical Treatment of Aggressive Periodontitis: Short‐Term Evaluation

Abstract: Etoricoxib did not promote additional improvement in the clinical parameters; however, it produced an initial reduction in the PGE(2) levels in the GCF, which could be related to the discrete improvement in the bone condition.

Cited by 21 publications

References 37 publications

Auxiliary chemical therapies in the treatment of aggressive periodontitis: current aspects

Auxiliary chemical therapies in the treatment of aggressive periodontitis: current aspects

Protective effect of topical Cordia verbenacea in a rat periodontitis model: immune-inflammatory, antibacterial and morphometric assays

Inibidores seletivos da cox-2 na odontologia: limitações e efeitos adversos

Contact Info

Product

Resources

About